Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0XBJHU)
| ADC Name |
LY3076226
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
LY3076226
Click to Show/Hide
|
|||||
| Organization |
ImmunoGen (Top20 MNC) (Originator);Eli Lilly (Top20 MNC)
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Structure |
|
|||||
| Antibody Name |
IMC-D11
|
Antibody Info | ||||
| Antigen Name |
Fibroblast growth factor receptor 3 (FGFR3)
|
Antigen Info | ||||
| Payload Name |
DM4
|
Payload Info | ||||
| Payload Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Sulfo-SPDB
|
Linker Info | ||||
| Conjugate Type |
Random Lysines
|
|||||
| Combination Type |
soravtansine
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible participants had advanced/metastatic cancer (Part B: FGFR3-altered bladder cancer), adequate organ function, and resolved prior treatment toxicities (Grade ≤1). Exclusions included recent investigational therapy, corneal/skin disorders (Grade ≥2), active infections, significant cardiac conditions (QTcF >480ms, NYHA III/IV), CNS metastases requiring steroids, or secondary malignancies impacting study interpretation. Reproductive-age participants adhered to contraception protocols.
Click to Show/Hide
|
||||
| Administration Dosage |
Part A (dose escalation in advanced cancer): LY3076226 administered intravenously (IV) on day 1 of each 21 day cycle. Part B (dose expansion in advanced urothelial carcinoma): LY3076226 administered IV on day 1 of each 21 day cycle.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02529553 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1 Study of LY3076226, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody-Drug Conjugate, in Patients With Advanced or Metastatic Cancer | ||||
| Primary Endpoint |
The MTD of LY3076226 was determined as the highest dose with <33% probability of DLT during Cycle 1 (21 days), establishing a safe dosing threshold for subsequent phases.
|
||||
| Other Endpoint |
PK analysis for Cmax and AUC was conducted pre- and postdose (0.05-72 hours) in Cycles 1 and 3. Tumor response (CR/PR per RECIST 1.1) was assessed through Cycle 3, day 21, with CR requiring complete lesion disappearance and PR a ≥30% target lesion reduction.
|
||||